Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Li G, Li X, Yin R, Feng M, Zuo J, Wei S, Kang S, Sun H, Li X, Wang Y, Zhang Y, Sun L, Lin D, Ruan X, Zhu Z, Jiang K, Liu H, Wang W, Hao D, Chen Y, Xiang S, Niu M, Wu L.
Li G, et al. Among authors: xiang s.
Gynecol Oncol. 2024 Oct 23;191:165-171. doi: 10.1016/j.ygyno.2024.10.001. Online ahead of print.
Gynecol Oncol. 2024.
PMID: 39447517
Free article.